Antivenom Market: By Product Type (Monovalent, Polyvalent), By Animal (Snake, Scorpions, Spiders, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Antivenom Market size was valued at USD 2.48 billion in 2023 and is poised to grow at a CAGR of 5.9% from 2024-2030. Antivenom is also called as antivenin. Antivenom is a medication prepared from antibodies that are used to treat certain venomous bites. Poisonous bites result in certain clinical conditions such as muscle weakness, secretion of excessive saliva, breathing problems, along other difficulties, in some instances that might lead to death as well. Antivenins are recommended only if there is significant toxicity or a high risk of toxicity. Antivenom is made by collecting venom from the relevant venomous species of spider, snake, and fish, injecting venom in small amounts to domestic animals and antibodies are separated from blood purification. These antibodies are used as antivenom. Growing demand for antivenom worldwide, especially in Africa and the Asia-Pacific region owing to a greater number of venomous bite incidents.

According to the World Health Organization (WHO), about 5 Mn snake bites occur each year, resulting 2.5 Mn envenomings (poisoning because of snake bites), a minimum of 100,000 deaths, and around three times as many amputations and other permanent disabilities. Withdrawal of antivenoms like Fav-Afrique by Pfizer further grew demand for the market. Market players are also actively involved in R&D to develop antivenoms and enhance their market position. In addition, many market players and institutions are actively involved in the development of new antivenoms. For instance, Equine F (ab') 2 in antivenin is being developed by Instituto Bioclon S.A (clinical trials phase 2) for the treatment of poisoning by a scorpion sting.

Based on the aforementioned factors market is expected to grow with a significant CAGR rate during the forecast period. Polyvalent anti-venoms are antibodies that can neutralize a variety of homologous venoms from different species/genera. In most circumstances and roughly 80% of the time when a monovalent antivenom cannot be chosen, polyvalent antivenoms can save the lives of snake envenomation victims, even when the perpetrator snake is unknown. Polyvalent anti-venoms are the most recommended anti-venom medication due to their evident advantages. Because of the current COVID-19 situation, all firms' research and development resources are being diverted to COVID-19 research, and there has been little or no research in this category in recent years, which will have an impact on market growth.

Global Antivenom Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.9%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Antivenom Market Dynamics

Increase in government initiatives to develop antivenoms and incidents of the venomous bites in undeveloped regions are fueling the growth of market over the forecast period. In addition, rise in deaths due to venomous bites and technological advancements in the development of antivenom creates significant opportunities for the antivenom manufacturers. However, complexity in regulatory procedures, insufficient funding in development of antivenom, and high cost of the product are hindering growth.

Global Antivenom Market Segmentation

By Product Type
  • Monovalent
  • Polyvalent
By Animal
  • Snake
  • Scorpions
  • Spiders
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

The global antivenom market size was valued at USD 2.48 billion in 2023

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

BTG Plc (U.K), Bharat Serum and Vaccines Limited (India), CSL Limited (Victoria), Vins Bioproducts Limited (India), Rare Disease Therapeutics, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Instituto Bioclon, S.A. de C.V.(Mexico), Incepta Vaccine Ltd. (Bangladesh), Merck & Co., Inc. (U.S), Pfizer Inc. (U.S.)

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Antivenom Market Introduction 
2.1.Global Antivenom Market  - Taxonomy
2.2.Global Antivenom Market  - Definitions
2.2.1.Product Type 
2.2.2.Animal
2.2.3.Distribution Channel
2.2.4.Region
3.Global Antivenom Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Antivenom Market Analysis 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Antivenom Market  By Product Type  2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Monovalent
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Polyvalent
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Antivenom Market  By Animal, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Snake
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Scorpions
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Spiders
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Antivenom Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Antivenom Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Antivenom Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Product Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Monovalent
9.1.2.Polyvalent
9.2.  Animal Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Snake
9.2.2.Scorpions
9.2.3.Spiders
9.2.4.Others
9.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Antivenom Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Monovalent
10.1.2.Polyvalent
10.2.  Animal Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Snake
10.2.2.Scorpions
10.2.3.Spiders
10.2.4.Others
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Antivenom Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Monovalent
11.1.2.Polyvalent
11.2.  Animal Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Snake
11.2.2.Scorpions
11.2.3.Spiders
11.2.4.Others
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Antivenom Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Monovalent
12.1.2.Polyvalent
12.2.  Animal Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Snake
12.2.2.Scorpions
12.2.3.Spiders
12.2.4.Others
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Antivenom Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Monovalent
13.1.2.Polyvalent
13.2.  Animal Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Snake
13.2.2.Scorpions
13.2.3.Spiders
13.2.4.Others
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Vins Bioproducts Limited (India)
14.2.2.Bharat Serum and Vaccines Limited (India)
14.2.3.CSL Limited (Victoria), Rare Disease Therapeutics, Inc. (U.S.)
14.2.4.F. Hoffmann-La Roche AG (Switzerland)
14.2.5.Instituto Bioclon, S.A. de C.V.(Mexico)
14.2.6.Incepta Vaccine Ltd. (Bangladesh)
14.2.7.BTG Plc (U.K)
14.2.8.Merck & Co., Inc. (U.S)
14.2.9.Pfizer Inc. (U.S.)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Vins Bioproducts Limited (India)
  • Bharat Serum and Vaccines Limited (India)
  • CSL Limited (Victoria), Rare Disease Therapeutics, Inc. (U.S.)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Instituto Bioclon, S.A. de C.V.(Mexico)
  • Incepta Vaccine Ltd. (Bangladesh)
  • BTG Plc (U.K)
  • Merck & Co., Inc. (U.S)
  • Pfizer Inc. (U.S.)

Adjacent Markets